With new mAb drugs such as Kadcyla costing over 100,000 Euros per year, the price per patient for these therapies is considerably more than small molecule drug treatments. One reason for this is that these therapies cost more to manufacture than small molecules. By using mini scale bioreactor models to determine optimum scale-up bioprocess parameters in fed-batch culture could speed up process development and reduce manufacturing costs.
Vetter has announced the opening of a new representative office in Singapore. The announcement...
AdvantaPass is used to transfer large volumes of fluids between clean rooms during...
Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-...
Pharmaceutical Processing’s Nov/Dec 2014 issue features an in-depth look at SAFC’s recently expanded high-potency API manufacturing facilities in Madison, WI. In addition, our Annual CMO/CSO Survey is included in this issue detailing the trends driving the CMO/CSO market. Other articles take a look at elastomeric closure in parenteral manufacturing, cleanroom energy efficiency, package integrity, deduster design efficiency, and desiccant canister design and feeding options.
The Sterile Process Design (SPD) vent has been optimized for use in critical single-use sterile filtration processes and offers a number of new features. The large knurled knob is easy to actuate with gloved hands, while multi-turn flow initiation allows for precise metering of flow during venting operations.
Biosimilars have increasingly become an important and somewhat controversial topic in the healthcare space. Depending on who one speaks to, the opinion on biosimilars changes. However, there are certain truths that all stakeholders should keep in mind.
SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facilities to neighboring Verona to rev up their high-potency API manufacturing capabilities.
Bristol-Myers Squibb and Lonza have announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, NH.
People want it all, don’t they? The type of cars many drive is one indicator. Crossover vehicles have become a very popular vehicle segment. They offer: practicality while still maintaining a cool factor; spaciousness with decent fuel efficiency; and car-like handling with the safety of all wheel drive for slippery conditions.
Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire AgreementOctober 23, 2014 10:31 am | News | Comments
The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.
PureFlex™ Plus film is a robust, durable film used in the construction of Mobius single-use process containers for biopharmaceutical manufacturing.
The October issue of Pharmaceutical Processing describes Capsugel’s merger with Bend Research and Encap to create a comprehensive solid dosage form solutions group. The issue also features articles on supply chain trends including how to reduce risk, managing a clinical supply chain, a look at the best printing and coding solutions, and the move to the fully connected enterprise. Other articles focus on particle size analysis, disposable chromatography technologies, and monitoring potency assays.
Finesse Solutions has announced the launch of SmartFactory, which is a uniquely configurable design architecture for single-use facilities. The Finesse SmartFactory is based on Finesse SmartParts, the measurement and actuation building blocks which comprise SmartSystem process automation solutions.
The September issue of Pharmaceutical Processing profiles SAFC’s new dry powder media manufacturing facility in Irvine, Scotland. In addition, coverage includes articles on highly toxic manufacturing and containment/isolator technologies. We also have a report on how CMOs are leading the adoption of new biopharm technologies. Other articles include a look at aseptic primary packaging, the challenges of scale-up and commercialization, optimizing vaccine processes, and the state of track and trace in the industry.
SAFC will contribute extensive expertise in conjugation and the manufacture of drug linkers, while BioPharma Solutions will offer world-class, sterile fill/finish services for final filling of ADC products.
Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics, to support the development of a series of new prescription pharmaceutical products for the treatment of ADHD using Catalent’s OSDrC® OptiDose™ drug delivery platform.
Baxter International has announced that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.
AMRI announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018.
Ajinomoto Althea announced today that it has officially received its European GMP certificate issued by the MHRA. The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial drug product for the European market.
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
The alliance is intended to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.
PhRMA launched a new Innovation Hub to showcase the latest data and research on innovation in the biopharmaceutical industry. The new Innovation Hub, accessible via www.Innovation.org, provides easy access to PhRMA resources related to the R&D process, the biopharmaceutical pipeline, and progress fighting diseases.
EMD Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Opens New Location in TokyoAugust 26, 2014 8:14 am | News | Comments
EMD Millipore today announced the opening of a new Biomanufacturing Sciences Training Center (BSTC) facility in Tokyo. The facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD Millipore.
Fitch Ratings expects that revenues from biologic therapies as a percentage of total pharmaceutical sales will continue to increase over the intermediate term as companies increase their prominence in their drug portfolios, according to a report published today.
The global biotechnology industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp increase in funds raised. However, much of the industry's growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts.
Researchers at the University of Michigan have obtained the first three-dimensional snapshots of the "assembly line" within microorganisms that naturally produces antibiotics and other drugs.
The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking the overall biologics market value from $162 billion in 2013 to more than $262 billion by 2019, says research and consulting firm GlobalData.
A global analysis of 238 biomanufacturers and 178 suppliers in 31 countries — the 514 page study is the industry's definitive, quantitative analysis and includes 11 years of biopharma trends and opportunities, including in-depth analysis of specific issues affecting the industry.
- Page 1